CKD Clinical Trial
Official title:
Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease（CKD）Patients With Heart Failure
This paper will mainly present the renal results from a clinical study aimed to observe the effect of sacubitril/valsartan in advanced chronic kedney disease patients with heart failure.All patients will receive LCZ696.The results will be compared before and after treatment.
On trial entry, patients will first receive LCZ696 50mg twice daily.According to the condition of disease and tolerance,the dose will be doubled every 2 weeks until the target maintenance dose 200mg twice daily is reached unless potassium or change in kidney function preclude a dose increase(reduction in dose will be permitted if the larger dose will not be tolerated, and temporary interruption will be permitted at any time if required for clinical reasons).The trial will be followed up for 12 weeks. Study visits will be scheduled at 2,4,6,8,10and12 weeks (and additional visits will be arranged where necessary to monitor participant safety). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03277911 -
Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases
|
N/A | |
| Active, not recruiting |
NCT04008810 -
Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
|
||
| Completed |
NCT05144971 -
StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
|
||
| Active, not recruiting |
NCT05356325 -
FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.
|
||
| Not yet recruiting |
NCT04491669 -
Screening of Gastrointestinal Tract Bleeding Causes Among Chronic Renal Failure Patients
|
||
| Completed |
NCT04709120 -
Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection
|
||
| Terminated |
NCT03277183 -
Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin
|
Phase 4 | |
| Enrolling by invitation |
NCT04491227 -
Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
|
||
| Recruiting |
NCT06279429 -
Sucrosomial Iron on Insomnia in Non-dialysis Chronic Kidney Disease Patients With Iron Deficiency Anemia
|
N/A | |
| Recruiting |
NCT03501745 -
Smart-CKD/BP Study
|
N/A | |
| Recruiting |
NCT04708743 -
The Tongue Features Associated With Chronic Kidney Disease
|
||
| Recruiting |
NCT06416761 -
Genetics in the Progression of Nephropathies
|
||
| Completed |
NCT04119570 -
CKD Report Card Pilot Trial
|
N/A | |
| Completed |
NCT06374043 -
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.
|
Phase 4 | |
| Not yet recruiting |
NCT06094920 -
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
|
Phase 4 | |
| Recruiting |
NCT04819217 -
Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease
|
N/A | |
| Completed |
NCT05970094 -
Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5
|
N/A | |
| Withdrawn |
NCT04782297 -
Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)
|
||
| Recruiting |
NCT05784389 -
Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5
|
N/A | |
| Recruiting |
NCT04630132 -
Renal Ageing-sarcopenia Network
|